Arbutus Biopharma Corp
Suletud
4.34 0.46
Ülevaade
Aktsiahinna muutus
24h
Min
4.25
Max
4.38
Sissetulek | 173M 170M |
|---|---|
Müük | 178M 179M |
P/E Sektori keskmine | 5.398 49.888 |
Aktsiakasum | 1.19 |
Kasumimarginaal | 94.735 |
Töötajad | 19 |
EBITDA | 177M 169M |
Järgmine tulemuste avaldamine | 5. aug 2026 |
|---|
Turukapital | 20M 885M |
|---|---|
Eelmine avamishind | 3.88 |
Eelmine sulgemishind | 4.34 |
Arbutus Biopharma Corp Graafik
Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.
Seotud uudised
Võrdlus sarnastega
Hinnamuutus
Arbutus Biopharma Corp Prognoos
Finantsandmed
Müügi- ja halduskulud
Tegevuskulud
Maksueelne kasum
Müük
Müügikulu
Brutokasum müügist
Intressikulud võla pealt
EBITDA
Ärikasum
$
Ettevõttest Arbutus Biopharma Corp
Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of imdusiran (AB-729), a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression. The company's research and development programs include AB-101, an oral PD-L1 inhibitor to reawaken patients' HBV-specific immune system; and small molecule antiviral medicines to treat coronaviruses, including COVID-19. It has licensing agreements with Gritstone Oncology, Inc; Alnylam Pharmaceuticals, Inc.; Qilu Pharmaceuticals Co, Ltd; Assembly Biosciences, Inc.; Acuitas Therapeutics, Inc.; and Antios Therapeutics, Inc. Arbutus Biopharma Corporation also has a clinical collaboration agreement with Barinthus Biotherapeutics plc to evaluate VTP-300. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Warminster, Pennsylvania.
